Mark Rutenberg

CDx Diagnostics, Inc. develops and delivers instruments for detection and prevention of cancers. It is a specialized pathology lab that utilizes patented CDx Technology to analyze a disaggregated tissue specimen of the entire thickness of the suspect epithelium. The firm involves in detection and prevention of cancers of the esophagus, oral cavity, pharynx, and larynx. CDx Diagnostics provides clinicians with unique tools to enhance their detection of precancerous change through complete epithelial sampling combined with computer-assisted morphological and molecular laboratory analysis. The company was founded by Mark Rutenberg and Drore Eisen in 1997 and is headquarters in Suffern, NY.

OralCDx Laboratories, Inc. manufactures cancer detection equipment and devices. The firm analyses technologies for detection of precursors of oral, laryngeal and esophageal cancer. Its products include EndoCDx LP and EndoCDz TNE, EndoCDx Esophagogastric, OralCDx Brush Biopsy and OralCDx. The company was founded by Mark Rutenberg in July, 1997 and is headquartered in Suffern, NY.

CDx Diagnostics, Inc. develops and delivers instruments for detection and prevention of cancers. It is a specialized pathology lab that utilizes patented CDx Technology to analyze a disaggregated tissue specimen of the entire thickness of the suspect epithelium. The firm involves in detection and prevention of cancers of the esophagus, oral cavity, pharynx, and larynx. CDx Diagnostics provides clinicians with unique tools to enhance their detection of precancerous change through complete epithelial sampling combined with computer-assisted morphological and molecular laboratory analysis. The company was founded by Mark Rutenberg and Drore Eisen in 1997 and is headquarters in Suffern, NY.

CDx Medical Holdings, Inc. engages in the provision of healthcare services. The company is headquartered in Suffern, NY.

CDx Medical Holdings, Inc. engages in the provision of healthcare services. The company is headquartered in Suffern, NY.

CDx Diagnostics, Inc. develops and delivers instruments for detection and prevention of cancers. It is a specialized pathology lab that utilizes patented CDx Technology to analyze a disaggregated tissue specimen of the entire thickness of the suspect epithelium. The firm involves in detection and prevention of cancers of the esophagus, oral cavity, pharynx, and larynx. CDx Diagnostics provides clinicians with unique tools to enhance their detection of precancerous change through complete epithelial sampling combined with computer-assisted morphological and molecular laboratory analysis. The company was founded by Mark Rutenberg and Drore Eisen in 1997 and is headquarters in Suffern, NY.

CDx Medical Holdings, Inc. engages in the provision of healthcare services. The company is headquartered in Suffern, NY.

CDx Diagnostics, Inc. develops and delivers instruments for detection and prevention of cancers. It is a specialized pathology lab that utilizes patented CDx Technology to analyze a disaggregated tissue specimen of the entire thickness of the suspect epithelium. The firm involves in detection and prevention of cancers of the esophagus, oral cavity, pharynx, and larynx. CDx Diagnostics provides clinicians with unique tools to enhance their detection of precancerous change through complete epithelial sampling combined with computer-assisted morphological and molecular laboratory analysis. The company was founded by Mark Rutenberg and Drore Eisen in 1997 and is headquarters in Suffern, NY.

CDx Medical Holdings, Inc. engages in the provision of healthcare services. The company is headquartered in Suffern, NY.

CDx Diagnostics, Inc. develops and delivers instruments for detection and prevention of cancers. It is a specialized pathology lab that utilizes patented CDx Technology to analyze a disaggregated tissue specimen of the entire thickness of the suspect epithelium. The firm involves in detection and prevention of cancers of the esophagus, oral cavity, pharynx, and larynx. CDx Diagnostics provides clinicians with unique tools to enhance their detection of precancerous change through complete epithelial sampling combined with computer-assisted morphological and molecular laboratory analysis. The company was founded by Mark Rutenberg and Drore Eisen in 1997 and is headquarters in Suffern, NY.